Browse the evidence

GLP-1 receptor agonists (specifically Liraglutide and Semaglutide) promote NASH resolution and reduce hepatic steatosis in patients with T2DM and NAFLD, primarily through weight loss and reduced de novo lipogenesis.

If lifestyle changes alone aren't enough to manage your fatty liver and diabetes, ask your doctor about GLP-1 medications like Liraglutide or Semaglutide. These drugs have been shown to significantly improve liver inflammation and fat content, with Semaglutide showing high rates of NASH resolution. They work by mimicking a gut hormone that helps regulate blood sugar and liver fat production.

Pioglitazone improves NASH resolution and fibrosis stages in patients with T2DM and NAFLD, but its use is limited by side effects such as weight gain and bone fracture risk.

Pioglitazone is a diabetes medication that can also improve liver inflammation and fibrosis in fatty liver disease. However, it can cause weight gain, swelling, and increase the risk of bone fractures. It is generally used when other treatments are not suitable or effective, and the benefits for the liver must be weighed against these risks.

Diet-induced weight loss reduces left ventricular mass (LVM) in adults with overweight or obesity, whereas adding moderate-to-vigorous physical activity (≥150 min/week) to diet-induced weight loss preserves LVM.

If you are overweight or obese, losing weight through diet alone will reduce your heart's muscle mass. However, if you combine that diet with at least 150 minutes of moderate-to-vigorous exercise per week, your heart muscle mass is preserved. Both outcomes may be favorable, but preserving heart mass through exercise might be a beneficial adaptation alongside weight loss.

Maintaining lower HbA1c levels (<7%) is associated with slower progression of biological aging, as measured by the deficit accumulation frailty index, over an 8-year period in adults with type 2 diabetes.

If you have type 2 diabetes, keeping your average blood sugar (HbA1c) below 7% is linked to slower biological aging and less physical decline over time compared to higher levels. Work with your doctor to achieve this target safely, as it appears to protect your long-term health.

Consistent use of metformin (≥50% of assessments) is independently associated with slower progression of the frailty index in adults with type 2 diabetes, after adjusting for HbA1c and weight loss.

Taking metformin consistently is linked to slower physical decline in people with type 2 diabetes, even after accounting for weight loss and blood sugar levels. Discuss with your doctor if metformin is the right long-term strategy for you.

Bariatric surgery significantly reduces all-cause mortality, disease-specific mortality (cancer, cardiovascular, diabetes), and major adverse cardiovascular events (MACEs) in patients with severe obesity compared to matched non-surgical controls.

For individuals with severe obesity, bariatric surgery is a highly effective intervention for reducing the risk of death from cancer, heart disease, and diabetes, as well as preventing major cardiovascular events. It offers superior long-term outcomes compared to lifestyle changes alone for this population. Patients should discuss these benefits with their healthcare providers to determine if they are candidates.

Regular physical exercise prevents age-related skeletal muscle dysfunction, including loss of strength and mitochondrial capacity, by inducing structural remodeling and metabolic adaptations.

Start or maintain regular physical activity, combining aerobic and resistance exercises, to protect your muscles from age-related decline. This is one of the most effective ways to maintain strength, mitochondrial health, and metabolic function as you age.

A lower n-6 to n-3 PUFA ratio (e.g., 5:1) shifts eicosanoid production toward anti-inflammatory mediators (resolvins, protectins), reducing cardiovascular disease risk, whereas the Western diet's high n-6/n-3 ratio promotes inflammation and atherosclerosis.

To reduce cardiovascular risk, aim to lower your intake of omega-6 fatty acids (common in vegetable oils) relative to omega-3s (from fish or algae). A ratio closer to 5:1 or lower is associated with less inflammation and lower CVD risk compared to the typical Western diet ratio.

GLP-1 receptor agonists for obesity treatment cause significant loss of lean body mass (approximately 20-25% of total weight reduction in men and 10-15% in women) and bone density, particularly when rapid weight loss occurs without structured resistance training.

If you are taking a GLP-1 medication for weight loss, you will likely lose some muscle along with fat. To protect your strength and metabolism, you must engage in resistance training (weight lifting) and ensure you are eating enough protein. This is especially important if you are losing weight quickly.

Modulating the gut microbiome and its metabolites through diet, pharmaceuticals (e.g., GLP-1 agonists, SGLT2 inhibitors), or microbiota therapies (e.g., probiotics, FMT) improves glycemic control and ameliorates Type 2 Diabetes complications by influencing pancreatic islet function, hepatic metabolism, and systemic inflammation.

To leverage the gut-diabetes connection, prioritize high-fiber diets to boost beneficial bacteria that produce short-chain fatty acids (SCFAs) and GLP-1. If lifestyle changes are insufficient, discuss GLP-1 receptor agonists (like semaglutide) or dual agonists (like tirzepatide) with your doctor, as these medications directly exploit the gut-pancreas axis to lower blood sugar and promote weight loss. Probiotics (specifically strains like Akkermansia muciniphila) may offer modest additional benefits, but they are not a replacement for core therapies.

Targeted pharmacotherapy with MC4R agonists (specifically setmelanotide) is efficacious and safe for reducing body weight and hunger in patients with specific genetic causes of obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome (BBS).

If you have been diagnosed with a specific genetic form of obesity (like POMC, LEPR, or BBS deficiency), ask your doctor about setmelanotide. This targeted drug has shown significant weight loss and hunger reduction in clinical trials for your specific genetic profile, unlike standard diets.

Anti-obesity medications and bariatric surgery improve Obstructive Sleep Apnea (OSA) severity, measured by Apnea-Hypopnea Index (AHI), in direct proportion to the percentage of body weight lost, regardless of the specific intervention type.

If you have OSA and are overweight, losing weight through medication or surgery will improve your sleep apnea severity. For every 1% of body weight you lose, your Apnea-Hypopnea Index (AHI) drops by about 0.45 events per hour. This benefit is consistent whether you lose the weight through medication or surgery, meaning you can choose the method that fits your lifestyle and risk tolerance while expecting similar proportional improvements in your sleep apnea.

Low-carbohydrate diets lead to significant short-term reductions in body weight, BMI, and waist circumference in overweight/obese T2DM patients, but these advantages may attenuate over the long term (6-24 months) compared to balanced low-calorie diets.

You can expect to lose weight, BMI, and waist circumference quickly in the first few months on a low-carb diet. However, do not be discouraged if your weight loss slows down after 6 months; studies show that over the long term, your results will likely be similar to those of any balanced, calorie-controlled diet. The key is sustainability and adherence rather than expecting indefinite rapid loss.

Tirzepatide utilization has rapidly displaced other glucose- and weight-lowering medications in the US, with its uptake being steeper and more sustained than previous GLP-1 receptor agonists.

Tirzepatide is currently the fastest-growing and most prescribed glucose- and weight-lowering medication in the US, rapidly replacing older drugs like metformin and other GLP-1s. If you have T2D or obesity, this drug is becoming the standard of care, but access may be difficult due to shortages. Prioritize securing a prescription early if eligible.

Retatrutide, a triple agonist of GLP-1, GIP, and glucagon receptors, achieves up to 24.2% weight loss over 48 weeks.

Retatrutide is an investigational once-weekly injection that targets GLP-1, GIP, and glucagon receptors, achieving up to 24.2% weight loss over 48 weeks in clinical trials. It is not yet fully approved but shows promise for obesity and type 2 diabetes. Potential side effects include gastrointestinal issues and transient heart rate elevations.

Intensive lifestyle intervention in patients with Type 2 Diabetes and obesity does not significantly reduce major cardiovascular events compared to standard care, although weight loss of 10% or more is associated with a lower risk.

For Type 2 Diabetes patients, intensive lifestyle changes alone may not significantly reduce heart events compared to standard care, unless you achieve at least 10% weight loss. Focus on sustainable weight loss and combine lifestyle changes with medical therapies for best heart protection.

GLP-1 Receptor Agonists (GLP-1RAs) improve glycemic control and promote weight loss by enhancing glucose-dependent insulin secretion, inhibiting glucagon, slowing gastric emptying, and reducing appetite via central nervous system pathways.

GLP-1RAs help control blood sugar and promote weight loss by mimicking a gut hormone that tells your body to release insulin when needed, slows down digestion, and reduces appetite. They are generally safe regarding low blood sugar but can cause stomach issues initially. Consistent use and monitoring are key to managing side effects and achieving long-term health benefits.

Regular physical activity, including aerobic, resistance, balance, and dual-task training, reduces the risk of dementia and cognitive decline by enhancing neurogenesis, improving cerebral blood flow, and increasing brain-derived neurotrophic factor (BDNF).

Aim for 150-300 minutes of moderate aerobic activity (like brisk walking) or 75-150 minutes of vigorous activity per week. Add strength and balance exercises twice a week. If you prefer cultural practices like Tai Chi or yoga, these are excellent alternatives that also support cognitive health. Start with what you enjoy and gradually increase intensity.

Adherence to Mediterranean (MedDiet) or MIND diets reduces the risk of cognitive decline and dementia by lowering inflammation and oxidative stress.

Eat more vegetables, fruits, legumes, nuts, and fish. Use olive oil instead of butter. Limit red meat and processed foods. This pattern helps reduce inflammation and supports brain health.

Post-procedure dietary quality (low processed foods, high fiber/vegetables) is more critical for sustained weight loss than the specific macronutrient ratio (low-carb vs. low-fat).

Don't obsess over whether you are low-carb or low-fat. Focus on eating whole foods, vegetables, and fruits, and keeping processed foods and added sugars under 10% of your calories. This quality matters more than the specific diet label.

Intermittent fasting variants (ADF, TWF, TRE) produce weight and fat loss effects equivalent to daily caloric restriction (DCR) when total energy intake is matched, with no inherent metabolic advantage to fasting timing.

Use intermittent fasting if it helps you eat less, not because you think it burns fat faster. If you can maintain a caloric deficit with standard meal timing, you will lose fat at the same rate. Prioritize protein intake and resistance training to protect muscle, as fasting does not inherently spare muscle.

GLP-1 receptor agonists and SGLT2 inhibitors are effective pharmacological treatments for T2DM and obesity that target shared pathophysiological mechanisms like inflammation and insulin resistance.

If lifestyle changes are insufficient, ask your doctor about GLP-1 agonists or SGLT2 inhibitors. These drugs help manage blood sugar and weight by targeting hormonal pathways, offering an advantage over older medications that may cause weight gain.

Current obesity treatments (behavioral, pharmacological, surgical) are effective but often result in weight regain, and their long-term success is limited by unchanged environmental factors.

Obesity treatments are effective but not permanent cures. You need to manage your weight long-term, possibly using a combination of treatments, and be prepared for potential weight regain if you stop.

GLP-1 receptor agonists (GLP-1RAs) improve hepatic steatosis, liver dysfunction enzymes, and glycemic control in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).

If you have fatty liver disease (MASLD/MASH), especially with diabetes or obesity, GLP-1 medications (like Semaglutide or Liraglutide) are a proven treatment option. They not only help lower blood sugar and promote weight loss but also directly improve liver health by reducing fat and inflammation. While lifestyle changes are foundational, these medications offer a powerful tool when lifestyle changes alone are insufficient or hard to maintain long-term. Consult your doctor to see if a GLP-1 RA is appropriate for your specific liver condition.